BEAM Stock Analysis: Buy, Sell, or Hold?
BEAM - Beam Therapeutics Inc. Common Stock
$26.81
-1.12 (-4.01%)
▼
5d:
-15.56%
30d:
-14.59%
90d:
-2.47%
WAIT
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Distribution
BEAM is up 10.1% this week, but smart money is buying puts. Top strike: $25 2026-06-18 with 81 OI. Put ratio: 65% View Scanner →
Strength: 6.6/10
Get Alerted When BEAM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BEAM is down 15.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BEAM is down 15.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BEAM is currently trading at $26.81, which is considered oversold relative to its 30-day fair value range of $28.46 to $31.71.
Technical Outlook: Technically, BEAM is showing sideways momentum. The price is currently testing key support at $26.64. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $51.13 (+83.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BEAM is showing sideways momentum. The price is currently testing key support at $26.64. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $51.13 (+83.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$28.46 -
$31.71
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
Protect Your Profits
Holding BEAM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.0%)
- BULLISH: Trading 83.1% below Wall St target ($51.13)
- WARNING: Recommendation downgraded due to -15.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$28.46 -
$31.71
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$26.64
Resistance Level
$34.38
Current Trend
Sideways
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.91
Wall Street Target
$51.13
(+83.1%)
Revenue Growth (YoY)
324.9%
Profit Margin
-40.2%
Share & Embed Analysis
Last updated: May 18, 2026 2:39 PM ET
Data refreshes hourly during market hours. Next update: 3:39 PM
Data refreshes hourly during market hours. Next update: 3:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BEAM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Amy Simon
SELL
6700 shares
2026-04-01
Christine Bellon
SELL
5956 shares
2026-04-01
Giuseppe Ciaramella
SELL
11810 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 50 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
Advanced BEAM Option Strategies
Professional options setups generated by AI based on today's BEAM price and gamma walls.
